These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 31425569)

  • 1. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
    Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
    Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
    Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
    Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
    Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
    Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
    Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer.
    Ha J; Kim MH; Jo K; Lim Y; Bae JS; Lee S; Kang MI; Cha BY; Lim DJ
    Medicine (Baltimore); 2017 Jul; 96(29):e7512. PubMed ID: 28723762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome.
    Ciappuccini R; Heutte N; Lasne-Cardon A; Saguet-Rysanek V; Leroy C; Le Hénaff V; Vaur D; Babin E; Bardet S
    BMC Cancer; 2020 Aug; 20(1):765. PubMed ID: 32799836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.
    Yim JH; Kim EY; Bae Kim W; Kim WG; Kim TY; Ryu JS; Gong G; Hong SJ; Yoon JH; Shong YK
    Thyroid; 2013 Jan; 23(1):58-63. PubMed ID: 22973946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
    Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
    Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
    Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
    Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
    Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulating thyroglobulin to TSH ratio predict long-term efficacy of
    Yin X; Lu C; Sun D; Ji Y; Wang Y; Zheng H; Ma Z; Jia Q; Tan J; Zheng W
    Endocrine; 2024 Jun; 84(3):1064-1071. PubMed ID: 38172344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer.
    Tian T; Jiang L; Zhang X; Huang R; Liu B
    Surgery; 2020 Dec; 168(6):1095-1100. PubMed ID: 32948335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.